NCT06065280View on ClinicalTrials.gov

Sodium-glucose Transport 2 Inhibitors (SGLT2i) in HFrEF Patients

NACompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

November 1, 2022

Primary Completion Date

December 1, 2024

Study Completion Date

December 30, 2024

Conditions
Heart FailureReduced Ejection Fraction Heart Failure
Interventions
DRUG

Empagliflozin 10 MG

Each group will be divided into 2 subgroups one on Empagliflozin and the other one on Dapagliflozin 10 MG daily.

DRUG

Dapagliflozin 10 MG

Each group will be divided into 2 subgroups one on Empagliflozin and the other one on Dapagliflozin 10 MG daily.

Trial Locations (1)

31527

Damanhour Teaching Hospital, General Organization for Teaching Hospitals and Institutes., Damanhūr

All Listed Sponsors
lead

Damanhour University

OTHER